Tags : Biosimilar Candidates

Mundipharma Collaborates with Samsung Bioepis to Commercialize Multiple Biosimilar Candidates

Tuba Khan January 13, 2020

Shots: Mundipharma to get exclusive commercialization rights for Samsung Bioepis’ first-wave biosimilar candidates in Taiwan and Hong Kong while Samsung Bioepis will remain MAH, responsible for the development, regulatory and […]readmore

Biosimilars

Yas Holding to Acquire Stake in Alvotech and Signs an

Tuba Khan November 4, 2019

Shots: Alvotech to receive ~$45M as up front, equity investment, milestone while Yas Holding has acquired a 2.5% stake in Alvotech business and get rights to commercialize Alvotech’s three biosimilar […]readmore

Tags : Biosimilar Candidates

Mundipharma Collaborates with Samsung Bioepis to Commercialize Multiple Biosimilar Candidates

Yas Holding to Acquire Stake in Alvotech and Signs an

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : Biosimilar Candidates

Mundipharma Collaborates with Samsung Bioepis to Commercialize Multiple Biosimilar Candidates

Yas Holding to Acquire Stake in Alvotech and Signs an

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company